ArticleArchives of toxicology2026
In vitro formation kinetics of two 2,5-dimethylfuran phase-I metabolites: cis-3-hexene-2,5-dione and 5-methylfurfuryl alcohol.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
2,5-Dimethylfuran (DMF) is a heat-induced contaminant found in various thermally processed foods. Due to its structural similarity to furan, a well-known hepatotoxin and potential human carcinogen, the presence of DMF in food poses a potential risk to consumers. DMF undergoes cytochrome P450 (CYP)-mediated biotransformation leading to the formation of two primary phase-I metabolites: the reactive cis-3-hexene-2,5-dione (HDO), which can react with cellular nucleophiles, and the primary alcohol 5-methylfurfuryl alcohol (MFA), formed after hydroxylation of the alkyl moiety. To deduce the in vitro formation kinetics of these two phase-I metabolites, we utilised a newly developed HPLC-ESI-MS/MS method to quantify HDO after scavenging with glutathione and monitored the formation of MFA by GC-MS in parallel. Metabolic activation and the formation of HDO was the predominant biotransformation pathway in human liver microsomes, whereas the parallel formation of MFA was significantly less efficient. In line with data on the metabolic activation of furan, CYP2E1 was the most active human CYP-isoform in the potential metabolic activation of DMF. However, CYP3A4 and CYP2D6 also contributed to the HDO formation in vitro. Hydroxylation of DMF and formation of MFA were exclusively catalysed by CYP2E1. Despite the formation of MFA as an alternative metabolic pathway, our kinetic data indicate that DMF is primarily metabolised by CYP2E1 to the reactive cis-enedial intermediate HDO, particularly at physiologically relevant concentrations. Therefore, exposure to DMF may contribute to the overall risk associated with dietary exposure to furans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.